

Product datasheet for **TR312253**

IFI27 Human shRNA Plasmid Kit (Locus ID 3429)

Product data:

| | |
|---------------------------|---|
| Product Type: | shRNA Plasmids |
| Product Name: | IFI27 Human shRNA Plasmid Kit (Locus ID 3429) |
| Locus ID: | 3429 |
| Synonyms: | FAM14D; ISG12; ISG12A; P27 |
| Vector: | pRS (TR20003) |
| E. coli Selection: | Ampicillin |
| Mammalian Cell Selection: | Puromycin |
| Format: | Retroviral plasmids |
| Components: | IFI27 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 3429). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| RefSeq: | <u>BC015492</u> , <u>NM_001130080</u> , <u>NM_001288952</u> , <u>NM_001288954</u> , <u>NM_001288956</u> , <u>NM_001288957</u> , <u>NM_001288958</u> , <u>NM_001288959</u> , <u>NM_001288960</u> , <u>NM_001288995</u> , <u>NM_005532</u> , <u>NM_005532.1</u> , <u>NM_005532.2</u> , <u>NM_005532.3</u> , <u>NM_005532.4</u> , <u>NM_001130080.1</u> , <u>NM_001130080.2</u> , <u>NM_001288960.1</u> , <u>NM_001288959.1</u> , <u>NM_001288954.1</u> , <u>NM_001288957.1</u> , <u>NM_001288958.1</u> , <u>NM_001288952.1</u> , <u>NM_001288956.1</u> , <u>BM756566</u> , <u>BM841506</u> , <u>BM841596</u> , <u>NM_001366993</u> , <u>NM_001366994</u> , <u>NM_001288957.2</u> , <u>NM_001288995.2</u> , <u>NM_001288959.2</u> , <u>NM_001288956.2</u> , <u>NM_001288954.2</u> , <u>NM_001288952.2</u> , <u>NM_001288958.2</u> , <u>NM_005532.5</u> , <u>NM_001130080.3</u> , <u>NM_001288960.2</u> |
| UniProt ID: | <u>P40305</u> |



[View online »](#)

| | |
|--------------------------------|--|
| Summary: | <p>Probable adapter protein involved in different biological processes (PubMed:22427340, PubMed:27194766). Part of the signaling pathways that lead to apoptosis (PubMed:18330707, PubMed:27673746, PubMed:24970806). Involved in type-I interferon-induced apoptosis characterized by a rapid and robust release of cytochrome C from the mitochondria and activation of BAX and caspases 2, 3, 6, 8 and 9 (PubMed:18330707, PubMed:27673746). Also functions in TNFSF10-induced apoptosis (PubMed:24970806). May also have a function in the nucleus, where it may be involved in the interferon-induced negative regulation of the transcriptional activity of NR4A1, NR4A2 and NR4A3 through the enhancement of XPO1-mediated nuclear export of these nuclear receptors (PubMed:22427340). May thereby play a role in the vascular response to injury (By similarity). In the innate immune response, has an antiviral activity towards hepatitis C virus/HCV (PubMed:27194766, PubMed:27777077). May prevent the replication of the virus by recruiting both the hepatitis C virus non-structural protein 5A/NS5A and the ubiquitination machinery via SKP2, promoting the ubiquitin-mediated proteasomal degradation of NS5A (PubMed:27194766, PubMed:27777077). [UniProtKB/Swiss-Prot Function]</p> |
| shRNA Design: | <p>These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.</p> |
| Performance Guaranteed: | <p>OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.</p> <p>For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).</p> |